FDMT: 4D Molecular Therapeutics, Inc.
About
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Current Value
$8.751 Year Return
Current Value
$8.751 Year Return
Key Details
Market Cap
$450.58M
P/E Ratio
-3.17
1Y Stock Return
-27.45%
1Y Revenue Growth
1014.45%
Dividend Yield
0.00%
Price to Book
0.8
Strategies that include FDMT
Stock's related to FDMT
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SOHU | 0.02% | $406.50M | +43.52% | 0.00% |
| BTI | 0.03% | $81.54B | +16.13% | 8.08% |
| HSY | -0.03% | $34.45B | -10.68% | 3.21% |
| CHTR | -0.04% | $54.72B | -4.38% | 0.00% |
| PEP | 0.04% | $215.02B | -6.60% | 3.35% |
| ECL | 0.04% | $69.18B | +30.92% | 0.93% |
| VLRS | 0.09% | $950.73M | +23.84% | 0.00% |
| TW | 0.09% | $28.66B | +42.39% | 0.29% |
| MGY | -0.11% | $5.36B | +26.87% | 1.90% |
| NOMD | 0.12% | $2.74B | +4.53% | 2.67% |
| YETI | 0.12% | $3.22B | -10.71% | 0.00% |
| SXC | -0.13% | $1.05B | +39.93% | 3.52% |
| PULM | -0.13% | $19.83M | +202.98% | 0.00% |
| ENR | -0.14% | $2.67B | +21.02% | 3.21% |
| ICL | 0.16% | $5.65B | -14.79% | 4.46% |
| PINS | -0.16% | $20.07B | -5.95% | 0.00% |
| HE | -0.18% | $1.82B | -17.47% | 0.00% |
| INN | -0.18% | $661.35M | -1.61% | 4.92% |
| NWN | -0.21% | $1.68B | +15.26% | 4.67% |
| TTE | -0.23% | $138.45B | -11.95% | 5.50% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| APD | -42.03% | $72.92B | +18.69% | 2.14% |
| MCD | -17.86% | $208.34B | +3.66% | 2.30% |
| DMLP | -14.63% | $1.58B | +18.00% | 10.54% |
| VIRT | -14.49% | $3.17B | +110.38% | 2.60% |
| FRHC | -12.91% | $7.09B | +39.10% | 0.00% |
| CBOE | -12.22% | $21.46B | +15.84% | 1.11% |
| TXO | -12.02% | $737.26M | -1.80% | 13.22% |
| KDP | -11.25% | $42.76B | -1.22% | 2.77% |
| CME | -10.87% | $82.76B | +9.21% | 1.98% |
| SJM | -10.47% | $11.91B | -0.25% | 3.82% |
| SGML | -10.36% | $1.54B | -51.62% | 0.00% |
| GFS | -10.33% | $23.54B | -24.98% | 0.00% |
| DOCU | -10.33% | $16.14B | +87.11% | 0.00% |
| HRL | -9.88% | $16.30B | -8.38% | 3.81% |
| HUSA | -9.21% | $16.69M | -11.56% | 0.00% |
| ADM | -9.19% | $25.34B | -28.13% | 2.82% |
| QLYS | -9.14% | $5.18B | -21.75% | 0.00% |
| GIS | -8.88% | $34.85B | -2.91% | 3.78% |
| VZ | -8.86% | $176.51B | +12.56% | 6.37% |
| UUU | -8.75% | $4.97M | -41.89% | 0.00% |
ETF's related to FDMT
News
SeekingAlpha
Akebia Therapeutics expands market share with strong Q3 results. See why AKBA stock is gaining momentum, despite potential competition post-2025.
Yahoo
EMERYVILLE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced that management will participate in fireside chats at upcoming investor conferences in November and December and will present at the Ophthalmology Innovation Summit XIV. Members of the management team will also be available
Yahoo
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of -17.91% and 99.76%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Presented positive interim data for 4D-150 in wet age-related macular degeneration (wet AMD) from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and intraocular inflammation (IOI) profile numerically similar to approved anti-VEGF agents 4D-150 4FRONT Phase 3 program in wet AMD designed to maximize probability of success, continues to be on track with 4FRONT-1 trial initiation expected in Q1 2025 Continuing KOL engagement to exp
Yahoo
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Yahoo
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.